Journal
CANCERS
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers12020352
Keywords
ULK1; autophagy; cancer; drug resistance
Categories
Funding
- Key Research and Development Plan of Shaanxi Province [2017ZDXL-NY-0304, 2019ZDLNY01-02-02]
- National Key R&D Program of China [2017YFE0105300]
- China Agriculture Research System [CARS-29-jg-3]
- Shaanxi Provincial Natural Science Foundation [2018JQ3054]
Ask authors/readers for more resources
The difficulty of early diagnosis and the development of drug resistance are two major barriers to the successful treatment of cancer. Autophagy plays a crucial role in several cellular functions, and its dysregulation is associated with both tumorigenesis and drug resistance. Unc-51-like kinase 1 (ULK1) is a serine/threonine kinase that participates in the initiation of autophagy. Many studies have indicated that compounds that directly or indirectly target ULK1 could be used for tumor therapy. However, reports of the therapeutic effects of these compounds have come to conflicting conclusions. In this work, we reviewed recent studies related to the effects of ULK1 on the regulation of autophagy and the development of drug resistance in cancers, with the aim of clarifying the mechanistic underpinnings of this therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available